Multiplexed Prostate Cancer Companion Diagnostic Devices
Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Sensors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8220/21/15/5023 |
| _version_ | 1797525135955066880 |
|---|---|
| author | Josephine Aidoo-Brown Despina Moschou Pedro Estrela |
| author_facet | Josephine Aidoo-Brown Despina Moschou Pedro Estrela |
| author_sort | Josephine Aidoo-Brown |
| collection | DOAJ |
| description | Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay (ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the required sample volume, in the complexity of the analytical procedures, and in adding to the cost. Using companion diagnostic devices such as biosensors, which can be portable and cost-effective with multiplexing capacities, may address these limitations. This review explores recent research for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor platforms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in this review. In addition, this review discusses the importance of converting research protocols into multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a more personalized approach to PCa patients’ diagnostic, surveillance and treatment management. |
| first_indexed | 2024-03-10T09:09:26Z |
| format | Article |
| id | doaj.art-b99a19d4a21e4061b0f0dcaaa1202742 |
| institution | Directory Open Access Journal |
| issn | 1424-8220 |
| language | English |
| last_indexed | 2024-03-10T09:09:26Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Sensors |
| spelling | doaj.art-b99a19d4a21e4061b0f0dcaaa12027422023-11-22T06:09:19ZengMDPI AGSensors1424-82202021-07-012115502310.3390/s21155023Multiplexed Prostate Cancer Companion Diagnostic DevicesJosephine Aidoo-Brown0Despina Moschou1Pedro Estrela2Centre for Biosensors, Bioelectronics and Biodevices (C3Bio), Department of Electronic & Electrical Engineering, University of Bath, Claverton Down, Bath BA2 7AY, UKCentre for Biosensors, Bioelectronics and Biodevices (C3Bio), Department of Electronic & Electrical Engineering, University of Bath, Claverton Down, Bath BA2 7AY, UKCentre for Biosensors, Bioelectronics and Biodevices (C3Bio), Department of Electronic & Electrical Engineering, University of Bath, Claverton Down, Bath BA2 7AY, UKProstate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully. One enhancement could include the simultaneous detection of multiple PCa-associated protein biomarkers alongside PSA, also known as multiplexing. If conventional methods such as the enzyme-linked immunosorbent assay (ELISA) are used, multiplexed detection of such protein biomarkers can result in an increase in the required sample volume, in the complexity of the analytical procedures, and in adding to the cost. Using companion diagnostic devices such as biosensors, which can be portable and cost-effective with multiplexing capacities, may address these limitations. This review explores recent research for multiplexed PCa protein biomarker detection using optical and electrochemical biosensor platforms. Some of the novel and potential serum-based PCa protein biomarkers will be discussed in this review. In addition, this review discusses the importance of converting research protocols into multiplex point-of-care testing (xPOCT) devices to be used in near-patient settings, providing a more personalized approach to PCa patients’ diagnostic, surveillance and treatment management.https://www.mdpi.com/1424-8220/21/15/5023prostate cancermultiplex point-of-care testing (xPOCT)protein biomarkerscompanion diagnostic devices |
| spellingShingle | Josephine Aidoo-Brown Despina Moschou Pedro Estrela Multiplexed Prostate Cancer Companion Diagnostic Devices Sensors prostate cancer multiplex point-of-care testing (xPOCT) protein biomarkers companion diagnostic devices |
| title | Multiplexed Prostate Cancer Companion Diagnostic Devices |
| title_full | Multiplexed Prostate Cancer Companion Diagnostic Devices |
| title_fullStr | Multiplexed Prostate Cancer Companion Diagnostic Devices |
| title_full_unstemmed | Multiplexed Prostate Cancer Companion Diagnostic Devices |
| title_short | Multiplexed Prostate Cancer Companion Diagnostic Devices |
| title_sort | multiplexed prostate cancer companion diagnostic devices |
| topic | prostate cancer multiplex point-of-care testing (xPOCT) protein biomarkers companion diagnostic devices |
| url | https://www.mdpi.com/1424-8220/21/15/5023 |
| work_keys_str_mv | AT josephineaidoobrown multiplexedprostatecancercompaniondiagnosticdevices AT despinamoschou multiplexedprostatecancercompaniondiagnosticdevices AT pedroestrela multiplexedprostatecancercompaniondiagnosticdevices |